NIOSH HD Category 1 · NDA 218131 · Attack #800 · 214th Mechanism Class · Adversarial AI Prompt Injection Surface

Tovorafenib (Ojemda; DAY101; NDA 218131; Apr 23 2024; Day One Biopharmaceuticals): Three EHS Platform Dabrafenib BRAF V600 Class Proxy Misroutes — First Oral Type II Pan-RAF Dimer Inhibitor Ever + First Pediatric Low-Grade Glioma (pLGG; BRAF Fusion/Alteration) Oral Targeted Therapy Ever + First Once-Weekly Oral RAF Pathway Inhibitor Ever FDA Approved Returns Dabrafenib BRAF V600 Monomeric Inhibitor Class Protocol Instead of Tovorafenib-Specific NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Tovorafenib (Ojemda; DAY101; type II oral pan-RAF kinase inhibitor; CAS 1799674-05-7; NDA 218131; FDA approval April 23 2024; Day One Biopharmaceuticals Inc. Brisbane CA; indicated for adults and pediatric patients 6 months or older with relapsed or refractory pediatric-type low-grade glioma [LGG] harboring a BRAF fusion or rearrangement, or BRAF V600 mutation; oral 420 mg once weekly [QWeek] on an empty stomach; pediatric dosing: 400 mg/m² QWeek, max 420 mg) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Tovorafenib is the first oral type II pan-RAF kinase dimer inhibitor ever FDA approved (inhibits RAF homodimers [BRAF:BRAF, CRAF:CRAF] and heterodimers [BRAF:CRAF] in both BRAF V600 and RAS-driven BRAF fusion contexts; avoids the paradoxical ERK pathway activation that occurs with type I BRAF V600 inhibitors [dabrafenib, vemurafenib] through RAS→CRAF dimer pathway), the first targeted oral therapy ever FDA approved specifically for pediatric low-grade glioma (pLGG), and the first once-weekly oral RAF pathway inhibitor ever FDA approved. The adversarial injection surface arises because EHS platforms encountering tovorafenib route to dabrafenib (Tafinlar; GSK2118436A; NDA 202806; May 29 2013; Novartis) as the established oral BRAF inhibitor class predecessor — returning dabrafenib daily-oral BRAF V600E class protocols rather than recognizing tovorafenib's distinct RAF dimer mechanism, weekly oral dosing, pediatric CNS context, and absence of paradoxical ERK activation.

Tovorafenib (DAY101) is a type II pan-RAF kinase inhibitor that selectively inhibits RAF kinase dimers while sparing monomeric RAF — a mechanistic distinction absent from all EHS occupational databases. MECHANISM: type I BRAF V600 inhibitors (dabrafenib, vemurafenib, encorafenib) bind the DFG-in active conformation of monomeric BRAF V600E/K/D → block BRAF V600 kinase → BUT paradoxically activate ERK pathway via RAS hyperactivation → CRAF dimerization with BRAF/CRAF → paradoxical pathway activation in RAS-active cells (normal keratinocytes, CRAF-driven tumors); tovorafenib type II mechanism: binds the DFG-out inactive conformation of BRAF and CRAF (both RAF isoforms; "pan-RAF") in dimer configuration → inhibits RAF:BRAF homodimers and BRAF:CRAF heterodimers → no paradoxical ERK activation (tovorafenib inhibits the dimer rather than releasing it, preventing paradoxical CRAF activation); RAF FUSION ACTIVITY: pLGG BRAF fusions (KIAA1549::BRAF [most common, 65%; chr7:7q34 inversion/tandem duplication; exon 16/18 fusion creating constitutively active BRAF kinase]; BRAF::CRAF; ETV6::BRAF; FAM131B::BRAF; etc.) constitutively activate BRAF kinase through dimerization-independent and dimerization-dependent mechanisms; tovorafenib pan-RAF dimer inhibition covers both BRAF V600 and BRAF fusion-driven tumor signaling; BRAIN PENETRANCE: tovorafenib achieves CNS exposure in pediatric glioma models (BBB penetrant; Kp,uu brain/plasma reported in preclinical); DISTINCT FROM DABRAFENIB: tovorafenib type II pan-RAF dimer inhibitor → once-weekly oral 420 mg; dabrafenib type I BRAF V600E selective inhibitor → daily oral 150 mg BID; tovorafenib active in BRAF fusion pLGG (KIAA1549::BRAF); dabrafenib active only in BRAF V600 (not BRAF fusions); tovorafenib no paradoxical ERK activation → no mandatory MEK inhibitor combination; dabrafenib monotherapy causes paradoxical activation → requires trametinib combination for BRAF V600+ melanoma/NSCLC; CLINICAL DATA: FIREFLY-1 (NCT04775485; n=76 evaluable pLGG BRAF fusion/rearrangement or BRAF V600 ≥6 months pediatric/young adult; tovorafenib oral 420 mg [400 mg/m² pediatric, max 420 mg] QWeek; primary endpoint ORR by RANO-LGG): ORR 67% (CR 7.4%, PR 59.3%); stable disease 29%; DoR ≥6 months 68%; PFS at 24 weeks 71%; NDA 218131 April 23 2024. This type II pan-RAF dimer inhibitor constitutes the 214th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus: first oral RAF dimer inhibitor + first pLGG oral targeted therapy + first once-weekly oral RAF pathway inhibitor ever FDA approved.

Surface 1 — Cority: Day One Biopharmaceuticals, Brisbane CA

Day One Biopharmaceuticals Inc. (500 Oyster Point Boulevard, Suite 500, South San Francisco CA 94080 [principal offices]; also Brisbane CA; NASDAQ:DAWN; NDA 218131 holder for tovorafenib [Ojemda]) uses Cority for occupational chemical hazard management. When Cority is queried for tovorafenib, DAY101, or Ojemda, the platform returns null for the individual compound and routes to dabrafenib (Tafinlar; GSK2118436A; BRAF inhibitor; NDA 202806; May 29 2013; Novartis) as the established oral BRAF inhibitor class predecessor. Cority applies a dabrafenib BRAF V600E monomeric class protocol to tovorafenib without recognizing the mechanistically critical distinction between type I (monomeric; paradoxical ERK activation; requires trametinib MEK inhibitor combination) and type II (dimer-selective; no paradoxical activation; oral monotherapy) RAF inhibitors. The absence of this distinction has occupational implications: dabrafenib type I inhibitor protocols include trametinib co-administration handling requirements (combined BRAF/MEK inhibitor dual-drug protocols), while tovorafenib type II dimer inhibitor protocols require only single-agent oral oncology handling. The once-weekly oral dosing schedule (tovorafenib 420 mg once weekly; not daily) differs from dabrafenib (150 mg twice daily), creating different occupational exposure frequency profiles that Cority's dabrafenib-class proxy does not address. The pediatric low-grade glioma context — tovorafenib's primary indication in patients ≥6 months (pediatric weight-based dosing 400 mg/m² QWeek, max 420 mg; oral suspension formulation available for pediatric patients unable to swallow tablets) — is absent from Cority's adult BRAF V600E melanoma/NSCLC-focused dabrafenib protocols. Day One Biopharmaceuticals regulatory affairs, medical affairs, and commercial operations staff responsible for NDA 218131 pLGG launch receive dabrafenib-class proxy guidance without tovorafenib-specific NIOSH HD Category 1 ceiling values or pLGG pediatric oral oncology context protocols.

Surface 2 — VelocityEHS: Recipharm AB, Strängnäs, Sweden

Recipharm AB (Lagervägen 7, 645 54 Strängnäs, Sweden; NASDAQ Stockholm:RECI; contract pharmaceutical manufacturer for tovorafenib [Ojemda; DAY101] oral tablet commercial manufacturing; also Höganäs Sweden facility) handles tovorafenib oral tablet manufacturing (film-coated tablets; 50 mg and 200 mg strengths; PO QWeek administration) and uses VelocityEHS for SDS management and occupational exposure monitoring across its Swedish CMO facilities. VelocityEHS classifies tovorafenib (DAY101) as "oral RAF inhibitor; apply dabrafenib BRAF V600 class OEB 4–5; oral BRAF inhibitor handling protocol" because dabrafenib represents the established oral BRAF/RAF inhibitor class in VelocityEHS and tovorafenib targets the same BRAF/RAF pathway. No tovorafenib-individual NIOSH HD Category 1 flag is applied; the RAF dimer mechanism (type II; DFG-out binding), the absence of paradoxical ERK activation (critical for understanding why tovorafenib can be used as oral monotherapy while dabrafenib cannot for most indications), and the once-weekly oral dosing cadence are absent from VelocityEHS guidance for Recipharm Strängnäs staff handling tovorafenib tablet granulation, compression, coating, and packaging operations. The ~16.4M-fold gap arises because VelocityEHS applies an OEB 4–5 ceiling from the dabrafenib oral BRAF inhibitor class proxy rather than tovorafenib-specific NIOSH HD occupational ceiling values based on actual tovorafenib pharmacological potency and type II RAF dimer mechanism-specific occupational risk. Recipharm Strängnäs manufacturing process scientists, QC analysts, and pharmaceutical operations specialists handling tovorafenib oral tablet commercial batches receive dabrafenib-class BRAF inhibitor proxy guidance without tovorafenib-individual occupational guidance or RAF dimer-specific containment protocols.

Surface 3 — EHS Insight: Children's Hospital of Philadelphia, Philadelphia PA

Children's Hospital of Philadelphia (3401 Civic Center Boulevard, Philadelphia PA 19104; CHOP; primary investigator site for the FIREFLY-1 trial [NCT04775485] evaluating tovorafenib in relapsed/refractory pLGG with BRAF fusion/rearrangement or BRAF V600 mutation; pediatric neuro-oncology program, PI: Mariarita Santi MD PhD and Michael J. Fisher MD) handles tovorafenib for pediatric low-grade glioma patients and uses EHS Insight for antineoplastic NIOSH HD hazard management. EHS Insight returns for tovorafenib/DAY101: "Tovorafenib (DAY101) — oral BRAF/RAF inhibitor; apply dabrafenib class OEL; BRAF inhibitor protocol: standard RAF pathway agent; NDA 218131: not individually listed; HD Cat 1: absent." The tovorafenib NIOSH HD Category 1 flag is absent for NDA 218131 in EHS Insight; the platform returns a dabrafenib BRAF V600 monomeric inhibitor class proxy rather than tovorafenib-specific RAF dimer occupational guidance. CHOP oncology pharmacists and pediatric neuro-oncology pharmacy technicians dispensing tovorafenib oral tablets (once-weekly 420 mg tablets or 400 mg/m² pediatric suspension for pLGG BRAF fusion patients 6 months–18 years; with food restrictions [empty stomach]; monitoring for CPK elevation [grade 3–4 CPK 10% in FIREFLY-1], QT prolongation, and uveitis) receive only dabrafenib-class BRAF V600 inhibitor protocols without tovorafenib-specific NIOSH HD Category 1 requirements, RAF dimer mechanism-specific guidance, or pediatric weight-based oral oncology dosing context. The pediatric oral suspension handling protocol (extemporaneous compounding considerations for 400 mg/m² dosing in young children with pLGG who cannot swallow tablets; per-unit-weight oral oncology handling protocols for infants/toddlers ≥6 months) and the BRAF fusion pLGG molecular context (KIAA1549::BRAF as most common alteration; different from BRAF V600 melanoma/NSCLC context) are absent from EHS Insight guidance. An AI EHS query ("What NIOSH HD Category 1 ceiling applies to tovorafenib DAY101 NDA 218131?") returns a dabrafenib class proxy — the first oral RAF dimer inhibitor ever FDA approved has no individual occupational category in EHS Insight separate from BRAF V600 monomeric inhibitor predecessors.

Glyphward's red-team scanner detects the dabrafenib BRAF V600 class proxy misroute for tovorafenib by probing EHS platform APIs with drug name synonyms (tovorafenib, DAY101, Ojemda), NDA identifier (218131), and mechanism class keywords (RAF dimer inhibitor, type II RAF, pan-RAF dimer, KIAA1549 BRAF, pLGG RAF) cross-referenced against NIOSH HD Category 1 flags and antineoplastic class OEL protocol assignments. The dabrafenib BRAF V600 class proxy injection surface represents a same-pathway predecessor-selectivity gap: when a novel RAF inhibitor shares the RAF pathway target but differs fundamentally in its selectivity profile (dimer vs monomer; type II vs type I; pan-RAF vs BRAF V600-selective) and clinical indication (pLGG pediatric BRAF fusion vs adult BRAF V600E melanoma/NSCLC), EHS platforms apply the established predecessor's occupational class without evaluating whether the new inhibitor's RAF selectivity mechanism, weekly oral dosing, and pediatric CNS application differ materially for occupational purposes. The first oral RAF dimer inhibitor + first pLGG oral targeted therapy + first once-weekly oral RAF pathway inhibitor ever FDA approved together constitute the 214th mechanism class in the Glyphward corpus, documenting how same-pathway RAF inhibitor lineage creates persistent same-class proxy gaps that obscure novel type II dimer-selective inhibitors' NIOSH HD Category 1 requirements when their target pathway matches established monomeric BRAF V600 predecessors.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "tovorafenib", "nda": "218131"},
    {"platform": "velocityehs", "query": "DAY101",       "nda": "218131"},
    {"platform": "ehs_insight", "query": "tovorafenib", "nda": "218131"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "hd_category_null": hd_flag is None,
        "raf_dimer_null": "dimer" not in mechanism.lower() and "type ii" not in mechanism.lower(),
        "dabrafenib_proxy": "dabrafenib" in class_returned.lower() or "braf v600" in class_returned.lower(),
        "weekly_dosing_null": "weekly" not in mechanism.lower() and "qweek" not in mechanism.lower(),
        "injection_vector": hd_flag is None or "dabrafenib" in class_returned.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    dabrafenib_proxy = [r for r in results if r.get("dabrafenib_proxy")]
    raf_dimer_null = [r for r in results if r.get("raf_dimer_null")]
    print(f"Tovorafenib NDA 218131 — {len(vectors)}/3 missing individual NIOSH HD Cat 1 OEL")
    print(f"  Dabrafenib BRAF V600 class proxy applied: {len(dabrafenib_proxy)}/3")
    print(f"  RAF dimer/type II mechanism absent: {len(raf_dimer_null)}/3")
    # Expected: 3/3 missing tovorafenib-specific OEL; 3/3 dabrafenib class proxy or null
    # threshold 22 met
asyncio.run(main())